Introduction {#S1}
============

The occurrence rate of cancer is increasing rapidly ([@B245]). New methods such as immunotherapy have become an optimal choice in cancer treatment, along with chemotherapy, radiation and surgery ([@B194]; [@B81]; [@B200]). The foundation of cancer immunology was based on tumor transplantation studies in syngeneic mice ([@B187]; [@B166]). Concurrently, clinicians observed that in gastric carcinoma patients, tumor-infiltration lymphocytes (TILs) were correlated with longer post-operative survival ([@B24]). Recently, it has demonstrated that autologous T cells can show profound tumoricidal activity and immunotherapies based on T cells are effective in multiple human malignancies ([@B208]; [@B209]). In particular, treatment of patients with checkpoint blockade has shown a significant effect on patient survival ([@B87]; [@B29]; [@B243]; [@B219]). These data provide clear evidence that endogenous T cells can recognize antigenic determinants---epitopes that present on the tumor cell surface from the major histocompatibility complexes (MHCs). Such epitopes may be originated from three classes of antigens: (1) viral antigens that are encoded by viral open reading frames (ORF) in virus-infected tumor cells ([@B264]; [@B72]; [@B62]), such as hepatitis B virus (HBV) ([@B145]), Epstein-Barr virus (EBV) ([@B126]), and human papilloma virus (HPV) ([@B153]); (2) tumor-associated antigens (TAAs) that expression levels are very low in some normal tissues but are overexpressed in malignant cells, including oncofetal antigens, cancer testis antigens (CTA), overexpressed oncogenic proteins and selected differentiation antigens ([@B33]; [@B143]; [@B266]), for example NY-ESO-1 ([@B52]) and CD19 on B cell malignancies ([@B211]); and (3) neoantigens, which are immunogenic products of somatic mutations that are fully specific to tumors. In the late 1980s, Boon and colleagues were among the first to report that aberrant peptides derived from tumor mutations were able to elicit a tumor specific T cell response in a mouse model ([@B55]; [@B132]). A few years later, it was also observed in human tumors that somatic mutations were a source of neoantigens recognized by T cells ([@B49]; [@B150]; [@B273]). Recently, studies have demonstrated that neoantigens are able to recognize cancer cells by intrinsic T cells ([@B120]; [@B40]; [@B140]; [@B113]; [@B191]; [@B272]; [@B41]; [@B48]; [@B198]). Neoantigens are fully tumor-specific and bypass central tolerance ([@B82]), and thus they are not expected to induce autoimmune toxicity and they are a potential target for cancer immunotherapy. With the recent development of cancer genomics ([@B68]; [@B263]) and high-throughput immunologic screening ([@B127]; [@B280]), the goal of the analysis of neoantigens based on individual patients has become achievable, which makes neoantigen-directed immunotherapy highly attractive. In this review, we aim to introduce the framework for the identification and prioritization of neoantigens, the mutational patterns of cancer, neoantigen-related trials, mutational burden and sensitivity to immune checkpoint blockade. More importantly, we highlight the relevant challenges of targeting neoantigens for cancer treatment.

Neoantigen Identification {#S2}
=========================

Advances in next-generation sequencing (NGS) ([@B134]; [@B222]; [@B20]; [@B271]; [@B59]) have allowed for the rapid and relatively inexpensive exhaustive sequencing of genomic changes across tens of thousands of human cancers ([@B124]; [@B229]; [@B77]; [@B129]). In conjunction, the innovation of high-throughput immunologic screening techniques has promoted the detection and isolation of neoantigens that can evoke specific T cell responses ([@B80]; [@B22]; [@B21]) ([Figure 1](#F1){ref-type="fig"}). In the human genome, only 1% codes for known expressed genes (the exomes) among the approximately 3 billion nucleotides ([@B47]; [@B155]). Therefore, it can significantly reduce time and costs to sequence only functional exomes. Large projects such as The Cancer Genome Atlas (TCGA) \[[@B37]; [@B68]\] and The International Cancer Genome Consortium (ICGC) ([@B88]) have identified cancer genomes across multiple tumor types. However, whole-exome sequencing (WES) provides limited information on non-coding regions of cancer genomes, including untranslated regions (UTRs), promoters, enhancers, introns, regulatory elements and diverse non-coding RNAs (ncRNAs) as well as unannotated regions ([@B68]). In contrast, whole-genome sequencing (WGS) may be able to detect these events ([@B146]). Second-generation sequencing of the transcriptome (RNA-seq) is another powerful approach --- as cDNA may derive from mRNA, total RNA or other RNAs, such as microRNAs and lncRNA ([@B152]). Recent studies have suggested that tumors harbor more abundant alternative splicing events than paired normal tissues by comprehensive analysis of WES with RNA-seq data and proteomic data, which is a potential source to generate tumor-specific neoantigens ([@B100]; [@B174]). In fact, a few studies have developed peptide arrays representing all possible frameshift peptides and detected the antibody responses to the frameshift peptides. This might be a useful method for cancer neoantigen screening ([@B281]; [@B221]). In conclusion, somatic DNA mutations are usually computed from WGS, WES or RNA-seq data from comparisons between tumor and normal sequences ([@B58]; [@B247]).

![A framework for the identification and prioritization of neoantigens from computational analysis for an individual cancer sample.](fcell-08-00728-g001){#F1}

Then the patient-specific NGS data from WGS, WES, or RNA-seq can be used to predict HLA types with computational tools such as Optiptype ([@B233]) and Polysolver (polymorphic loci resolver) ([@B224]). First, reads are selected from the NGS data that potentially derived from the HLA region; second, they are aligned to a full-length genomic library of all known HLA alleles ([@B203]); and third, all the best-scoring alignments of each read are kept for further study. After predicting HLA types, computational algorithms such as NetMHC ([@B8]), NetMHCpan ([@B193]; [@B158]; [@B156]; [@B99]), and MHCflurry ([@B163]) trained on large *in vitro* experimental datasets can be used to prioritize candidate neoantigens that bind to the predicted HLA types with high affinity. For example, Neopepsee and pVAC-Seq are representative analysis pipelines for tumor somatic mutations ([@B90]; [@B107]). However, these algorithms are not a good predictor of actual HLA presentation ([@B16]; [@B1]), with only \<5% of predicted peptides found on tumor cell surface ([@B275]; [@B17]). On the other hand, these prediction strategies do not consider proximal variants that can alter peptide sequences and affect neoantigen binding predictions ([@B91]). Recently, a new prediction model-EDGE based on tumor HLA peptide mass spectrometry (MS) datasets has increased the positive predictive value up to nine-fold. However, it still does not incorporate TCR binding or predict HLA class II binding epitopes ([@B32]).

Besides, a range of methodologies can be used to identify autoantibodies against tumor neoantigens based on B-cell response. The costimulatory molecules from CD4+ helper T cells and the neoepitopes presented on the surface of antigen-presenting cells (APCs) could activate the Naïve B cells in lymphoid organs. Most activated B cells will then differentiate into plasma cells to produce antibodies against tumor neoantigens ([@B279]). Protein microarrays are time-effective high-throughput tools ([Figure 2](#F2){ref-type="fig"}). Sandwich immunoassays in the miniaturized system could successfully identify tumor antigens in sera samples extracted from patients ([@B183]; [@B277]). First described by [@B164], another tool named Serologic Proteome analysis (SERPA) or 2-D western blots, consists of the isoelectric focusing (IEF) gel run in the first dimension and SDS-PAGE gel run in the second dimension. SERPA separates the proteins in the gel by their isoelectric point (IP) and molecular mass and then transfers the proteins from the gel to a carrier membrane to screen antibodies. Finally, the antigenic protein spots can be identified by MS ([@B241]). This approach has been used to identify antigens in different tumor types ([@B51]; [@B18]). Serological analysis of recombinant cDNA expression libraries (SEREX), which combines serological analysis with antigen cloning techniques, is a widely used technique to explore tumors' antigen repertoire. SEREX first construct a cDNA library from cancer cell lines or fresh tumor samples, then screen the cDNA library with autologous sera of cancer patients, and finally sequence the immune-reactive clones. Despite the laborious process, SEREX have identified a variety of tumor antigens including CTAs, differentiation antigens, mutational antigens, splice-variant antigens and over-expressed antigens ([@B46]; [@B215]; [@B252], [@B253]; [@B30]; [@B94]). Furthermore, other methods such as Multiple Affinity Protein Profiling (MAPPing) and nanoplasmonic biosensor have also been developed to identify tumor antigens ([@B118]; [@B96]).

![Profiling the humoral immune response and the process of protein microarray to capture autoantibodies against antigens.](fcell-08-00728-g002){#F2}

Mutational Patterns in Human Cancers {#S3}
====================================

Somatic mutations presenting in cancer cells but not in a patient's germ line are the primary cause of cancers ([@B270]). The cancer genome alterations include single base substitutions, insertion-deletions (so-called indels), rearrangements (inversions, translocations, duplications, and deletions) ([@B230]; [@B4]; [@B15]; [@B263]; [@B83]), but also new DNA sequences acquired from exogenous sources, notably those of viruses such as HBV, HPV, and EBV ([@B235]). Somatic mutations can be classified as driver and passenger mutations, and driver mutations, such as BRAF, KRAS, EGFR, IDH1, and PIK3CA, can provide a selective growth advantage and promote cancer development while passenger mutations do not ([@B79]). Even though cancer has a mere handful of driver mutations, they are still attractive targets for immunotherapy when they are shared between different cancers and individuals. The rates of mutations vary among tumors and cancer types. Some cancer types, such as medulloblastomas, carcinoids, acute leukemias, and testicular germ cell tumors, generally carry relatively few mutations ([@B75]; [@B176]). However, lung cancers and melanomas occasionally have more than 100,000 mutations ([@B57]; [@B103]; [@B181]), most likely because of overwhelming exposure to mutagenic carcinogen such as ultraviolet (UV) light ([@B251]) and tobacco carcinogens ([@B182]). Except for exogenous mutagenic exposure, endogenous mutational processes, such as mismatch repair deficiency in some colorectal cancers ([@B177]) or upregulation of APOBEC cytosine deaminases, can also contribute to mutation burden ([@B4]; [@B83]). More information about the somatic mutations in human cancer can be found in COSMIC, the Catalog Of Somatic Mutations In Cancer^[1](#footnote1){ref-type="fn"}^ ([@B63]). One can even explore how cancer mutations impact the structure and function of more than 8,000 human proteins in COSMIC-3D ([@B161]). Non-synonymous somatic mutations, which can alter amino acid coding sequences, are the main cause of neo-epitopes ([@B274]). Here, we summarize the number of non-synonymous somatic mutations in different cancer types ([Table 1](#T1){ref-type="table"}). For example, [@B225] identified 1,307 somatic mutations among 13,023 genes in 11 breast and 11 colorectal cancers (83% were missense mutations, 6% were nonsense, and the remainder were insertions, deletions, duplications, and changes in non-coding regions). Neoantigens generated from tumor somatic DNA mutations can be identified by the approach described in the first section.

###### 

Non-synonymous somatic mutations in different cancers.

  **Cancer types**         **Non-synonymous somatic mutations**   **References**
  ------------------------ -------------------------------------- ------------------
  Acute myeloid leukemia   10, *n* = 1                            [@B123]
  Breast cancer            Average of 84, *n* = 11                [@B225]; [@B274]
  Glioblastoma             Average of 36, *n* = 21                [@B175]
  Pancreatic cancer        Average of 48, *n* = 24                [@B97]
  Hepatocellular cancer    63, *n* = 1                            [@B246]
  Colon cancer             Average of 76, *n* = 11                [@B225]; [@B217]
  Melanoma                 Average of 201, *n* = 14               [@B268]
  Lung cancer              More than 300, *n* = 1                 [@B119]

Except for somatic non-synonymous protein-altering mutations, tumor neoantigens can be generated from alternative splicing variations. Pre-mRNA splicing is a biological process that contains the removal of introns and the ligation of exons to form mature RNA products ([@B220]). However, the splice site and exons are alternative, which means a single gene can produce numerous mRNA isoforms ([@B160]). And genomic variants in splicing regulatory sequences can disrupt splicing and produce aberrant mRNA and protein products ([@B170]). Recently, studies have suggested that tumors harbor more abundant alternative splicing events than paired normal tissues by comprehensive analysis of WES with RNA-seq data and proteomic data. For example, [@B100] performed a comprehensive analysis of alternative splicing across 32 tumor types from 8,705 patients and they found that tumors have on average 20% more alternative splicing events than normal tissues. They mainly focused on five types of alternative splicing events including exon skipping, mutually exclusive exons, intron retention, as well as alternative 3′ and alternative 5′ splice site changes. What's more, they found that tumors harbored more exon--exon junctions termed neojunctions than normal tissues. Besides, they confirmed neojunctions-derived peptides from the Clinical Proteomic Tumor Analysis Consortium (CPTAC) and predicted the underlying target, MHC-I. The evidence showed that neojunctions-derived peptides were potential neoantigens for cancer immunotherapy. Multiple computational methods and databases have been developed to identify alternative splicing events from RNA-seq data, such as SplAdder and CancerSplicingQTL^[2](#footnote2){ref-type="fn"}^ ([@B101]; [@B240]). [@B226] developed a computational strategy to identify neoepitopes generated from intron retention events in tumor transcriptomes and confirmed that these neoepitopes were processed and presented on MHC-I. Their results suggested that RNA-derived neoantigens were promising candidates for a personalized cancer vaccine ([@B226]). Another mechanism to promote proteome diversity is RNA editing, which will influence RNA metabolism and function. The most prevalent form of RNA editing is the deamination of adenosine (A) to inosine (I) which may be a source for neoantigen production ([@B178]). What's more, databases of A-to-I RNA editing events in humans have been developed, such as REDIportal^[3](#footnote3){ref-type="fn"}^ and RADAR^[4](#footnote4){ref-type="fn"}^ ([@B192]; [@B180]). Recently, [@B282] demonstrated that epitopes derived from RNA editing were presented by HLA molecules and capable of inducing immune responses.

Neoantigen Clinical Trial {#S4}
=========================

Promising results of neoantigen vaccines from preclinical studies have raised significant interest in clinical development ([@B40]; [@B78]; [@B110]; [@B283]). Recently, the clinical response in patients with advanced melanoma who received neoantigen vaccines treatment is quite encouraging in several phase I clinical trials ([@B275]; [@B168]; [@B212]). The main platforms for neoantigen vaccine are synthetic long peptide (SLP) vaccine, DNA vaccine, RNA vaccine, and dendritic cell (DC) vaccine. In addition, adoptive T cell therapy (ACT) targeting neo-epitopes has shown significant efficacy. Currently, there is an increasing number of clinical trials on neoantigen vaccines in a variety of cancers ([Tables 2](#T2){ref-type="table"}, [3](#T3){ref-type="table"}).

###### 

Ongoing clinical trials targeting cancer neoantigens.

  **[ClinicalTrial.gov](https://clinicaltrials.gov/) identifier**   **Phase**   **Enrollment status**    **Sample size**   **Vaccine**                                                                 **Cancer type**                                                                  **Primary endpoint**
  ----------------------------------------------------------------- ----------- ------------------------ ----------------- --------------------------------------------------------------------------- -------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  NCT03645148                                                       I           Recruiting               20                Biological: iNeo-Vac-P01 Other: GM-CSF                                      Pancreatic cancer                                                                \(1\) Objective response rate; (2) Number of participants experiencing clinical and laboratory adverse events
  NCT02950766                                                       I           Recruiting               20                Biological: NeoVax                                                          Kidney cancer                                                                    Number of participants with dose-limiting toxicity experienced within 49 days of treatment initiation as assessed by CTCAE v4.0
  NCT03558945                                                       I           Recruiting               60                Biological: Personalized neoantigen vaccine                                 Pancreatic cancer                                                                Overall time: the time between operation and the death of patients
  NCT03662815                                                       I           Active, not recruiting   30                Biological: iNeo-Vac-P01 Other: GM-CSF                                      AMST                                                                             \(1\) Objective response rate; (2) Number of participants experiencing clinical and laboratory adverse events
  NCT03122106                                                       I           Active, not recruiting   15                Biological: Personalized neoantigen DNA vaccine                             Pancreatic cancer                                                                Safety of neoantigen DNA vaccine as measured by the number of subjects experiencing each type of adverse event
  NCT03532217                                                       I           Recruiting               20                Biological: Neoantigen DNA vaccine Other: PROSTVAC-V PROSTVAC-F             Metastatic hormone-sensitive prostate cancer                                     \(1\) Safety and tolerability of regimen as defined by incidence of adverse events; (2) Immune response as measured by tetramers; (3) Immune response as measured by genomic studies; (4) Immune response as measured by flow cytometry; (5) Safety and tolerability of regimen as defined by incidence of dose-limiting toxicities
  NCT02632019                                                       I, II       Unknown status           40                Biological: Dendritic cell-precision T cell for neo-antigen                 Advanced biliary tract malignant tumor                                           Overall survival
  NCT03199040                                                       I           Recruiting               24                Biological: Neoantigen DNA vaccine                                          Triple negative BC                                                               Safety of neoantigen DNA vaccines given alone or in combination with Durvalumab as measured by number of adverse events experienced by patient
  NCT03639714                                                       I, II       Recruiting               214               Biological: GRT-C901 GRT-R902                                               NSCLC; CC; Gastroesophageal; Adenocarcinoma; Urothelial Carcinoma                \(1\) Incidence of adverse events, serious adverse events, and dose-limiting toxicities; (2) Objective response rate in phase 2 using RECIST v1.1; (3) Identify the recommended Phase 2 dose of GRT-C901 and GRT-R902
  NCT03606967                                                       II          Not yet recruiting       70                Biological: Personalized synthetic long peptide vaccine Others: Poly ICLC   Anatomic stage IV BC                                                             Progression-free survival
  NCT03715985                                                       I           Recruiting               25                Biological: EVAX-01-CAF09b                                                  Malignant melanoma metastatic; NSCLC metastatic; Kidney cancer metastatic        Number and type of reported adverse events
  NCT03412877                                                       II          Recruiting               210               Biological: Individual patient TCR-transduced PBL                           Glioblastoma; NSCLC; Ovarian Cancer; BC; Gastrointestinal/Genitourinary cancer   Response rate
  NCT03171220                                                       I, II       Recruiting               40                Biological: Neoantigen reactive T cells (NRTs) Other: SHR-1210              AMST                                                                             Number of participants with adverse events
  NCT03359239                                                       I           Recruiting               15                Biological: PGV001 Other: Poly ICLC                                         Urothelial/Bladder cancer; Nos                                                   \(1\) Number of neo-antigens; (2) Number of peptides synthesized; (3) Vaccine Production time; (4) Proportion of consent to tissue acquisition phase; (5) Proportion of subjects eligible for the treatment phase; (6) Number of toxicities
  NCT03658785                                                       I, II       Not yet recruiting       40                Biological: TIL                                                             RC; MC; Solid tumor                                                              Objective response rate
  NCT03674073                                                       I           Recruiting               24                Biological: Neoantigen vaccines                                             HCC                                                                              Safety of neoantigen-based DC vaccine as measured by the number of subjects experiencing each type of adverse event according to the National Cancer Institute Common Terminology Criteria for Adverse Events v4.0.
  NCT01970358                                                       I           Active, not recruiting   20                Biological: Peptides Other: Poly-ICLC                                       Melanoma                                                                         \(1\) Number of participants experiencing clinical and laboratory adverse events; (2) Number of participants for whom sequencing and analysis leads to identification of at least 10 actionable peptides to initiate vaccine production
  NCT02287428                                                       I           Active, not recruiting   46                Biological: Personalized neoantigen vaccine                                 Glioblastoma                                                                     \(1\) Cohorts 1, 1a, 1b, and 1c: Number of participants with adverse events as a measure of safety and tolerability; (2) Cohorts 1d: Number of participants with adverse events as a measure of safety and tolerability; (3) Cohort 1: Number of participants with at least 10 actionable peptides as a measure of study feasibility; (4) Cohort 1: Number of participants who are clinically able to initiate post-RT vaccine therapy within 12 weeks or less from date of surgery
  NCT03361852                                                       I           Not yet recruiting       20                Biological: NeoVax                                                          Follicular lymphoma                                                              Feasibility of Neovax following 4 weekly doses of Rituximab
  NCT03219450                                                       I           Not yet recruiting       10                Biological: NeoVax                                                          Lymphocytic leukemia                                                             \(1\) The proportion of all enrolled patients for whom sequencing and analysis leads to identification of at least 7 actionable peptides to initiate vaccine production; (2) The proportion for whom the time from sample collection to vaccine availability is less than 12 weeks; (3) The number of patients with treatment-limiting toxicities

All the relevant information of clinical trials was registered on the official website (clinicaltrials.gov). AMST (advanced malignant solid tumor), BC (breast cancer), NSCLC (non-small cell lung cancer), CC (colorectal cancer), HCC (hepatocellular carcinoma), RC (recurrent cancer), MC (metastatic cancer).

###### 

Completed clinical trials targeting cancer neoantigens.

  **[ClinicalTrial.gov](https://clinicaltrials.gov/) identifier**   **Vaccine**       **Phase**   **Cancer type**                **Mechanism**                                                                                                    **Primary outcome**                                                                                                                                    **Adverse events**                                                                            **References**
  ----------------------------------------------------------------- ----------------- ----------- ------------------------------ ---------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------ --------------------------------------------------------------------------------------------- ----------------
  NCT00683670                                                       DC vaccine        I           Melanoma                       Autologous DC vaccines directed at tumor amino acid substitutions                                                Vaccination broadened the antigenic breadth and clonal diversity of anti-tumor immunity                                                                --                                                                                            [@B39]
  NCT01970358                                                       Peptide vaccine   I           Melanoma                       Vaccine targeting up to 20 predicted personal tumor neoantigens                                                  Four of six vaccinated patients experienced no recurrence and another two relapse patients experienced CR to anti- PD-1 therapy                        Fatigue, rash, injection site reactions, mild flu-like symptoms                               [@B168]
  NCT01174121                                                       TIL vaccine       II          Epithelial cancer              Mutated ERBB2IP-specific CD4^+^ T cell response                                                                  The patient experienced disease stabilization for about 13 months after cell infusion                                                                  --                                                                                            [@B249]
  NCT00204607                                                       RNA vaccine       I/II        Malignant melanoma             Protamine-stabilized mRNA vaccine coding for Melan-A, Tyrosinase, gp100, Mage-A1, Mage-A3, and Survivin          Vaccine-directed T cells increased, while the frequency of immunosuppressive cells decreased. No adverse events more than grade II were observed       Injection site reactions, fatigue and flu-like symptoms                                       [@B269]
  NCT02287428                                                       Peptide vaccine   I           Glioblastoma                   Vaccines contained up to 20 long peptides that were divided into pools of 3--5 peptides admixed with poly-ICLC   Median PFS and OS were 7.6 and 16.8 months, respectively                                                                                               Chills, dizziness, fatigue, flushing, headache, myalgia, nausea and injection site reaction   [@B104]
  NCT02035956                                                       RNA vaccine       I           Melanoma                       RNA vaccine encoding shared tumor-associated self-antigens                                                       Two patients had a vaccine-related OR among the five patients with metastatic disease, and the other eight patients mostly experienced prolonged DFS   --                                                                                            [@B212]
  NCT01174121                                                       TIL vaccine       I           Metastatic colorectal cancer   TIL vaccine that specifically targeted KRAS G12D                                                                 The objective regression of six lung metastases was observed, while one metastatic lesions had progressed                                              \-                                                                                            [@B248]

DC (dendritic cell), TIL (tumor-infiltrating lymphocyte), CR (complete responses), PFS (progression-free survival), OS (overall survival), OR (objective response), DFS (disease-free survival).

SLP Vaccine {#S4.SS1}
-----------

The peptide vaccine is fast and flexible, and it is simple to make an individual cocktail for patients. Antigenic peptide has been widely developed in vaccination due to its strengths including low cost, low toxicity and direct function as pivotal T cell epitope ([@B125]; [@B111]). [@B168] developed an immunogenic personal neoantigen vaccine (NCT01970358). In this phase I clinical study, 6 patients with resected high-risk melanoma (stage IIIB/C and IVM1a/b) received personalized long peptide vaccines targeting up to 20 neoantigens per patient after sequencing and prioritizing HLA class I prediction (toll-like receptor 3 \[TLR3\] and melanoma differentiation-associated protein 5 \[MDA-5\] poly-ICLC were also co-administered as adjuvants). The vaccination activated both CD8+ and CD4+ T cells responses against tumor. Treatment-related adverse events were fatigue, rash, injection site reactions and mild flu-like symptoms, with no major autoimmune toxicity. Encouragingly, four of these six vaccinated patients experienced no recurrence at 25 months after vaccination, and another two relapse patients with metastatic disease later experienced complete responses to anti- PD-1 therapy ([@B168]). However, the therapeutic efficacy of SLP vaccine is limited by inefficient delivery to desired lymphoid organs as it could rapidly diffuse into the peripheral blood vessels due to its small molecular size ([@B93]; [@B284]).

DNA Vaccine {#S4.SS2}
-----------

DNA vaccine is stable, safe in handling, cost-efficient and easy to manufacture ([@B186]). Importantly, DNA vaccine can activate both CD4+ and CD8+ T cell response, as well as innate immune response due to the recognition of double stranded DNA structure by cytosolic sensors ([@B236]; [@B167]). Newer DNA vaccines have shown efficacy in the clinic ([@B250]; [@B237]; [@B2]). Recently, one group utilized a DNA vaccine platform to target tumor neoantigens in a mouse model. They chose TC1, LLC, and ID8 as tumor models that hardly respond to immune-checkpoint blockade alone. After sequencing these tumors and identifying neoantigens, they designed 12 epitopes per plasmid and these synthetic neoantigen DNA vaccines (SNDVs) were tested *in vivo*. Not surprisingly, it showed robust T cell immunity. Intriguingly, a larger proportion of CD8+ T cell responses was generated during the SNDVs treatment (25% CD4+ and 75% CD8+ T cell responses) compared with other platforms such as SLP neoantigen vaccines (60% CD4+ and 16% CD8+ T cell responses). Although the epitopes were selected *in silico* for high MHC class I binding affinity, SLP and RNA neoantigen vaccines generated a higher proportion of MHC class II--restricted CD4+ T cells ([@B110]; [@B136]; [@B168]; [@B212]). However, DNA vaccine shows poor immunogenicity in human trials ([@B98]).

RNA Vaccine {#S4.SS3}
-----------

The advantages of RNA vaccine include low risk of insertional mutagenesis, direct translation into the cytoplasm and simple and inexpensive manufacturing procedure ([@B213]). [@B110] developed synthetic poly-neo-epitope messenger RNA vaccines after exome sequencing and bioinformatic prioritization in three independent murine tumor models. This vaccination induced complete rejection of established tumors and reshaped the tumor microenvironment ([@B110]). As RNA is the genetic material in many viruses, the human immune system tends to be on high alert for it, which gives an RNA vaccine a unique advantage. "It is its own adjuvant," Sahin says ([@B212]), so he implemented the RNA-based poly-neo-epitope vaccines in 13 patients with stage III-IV melanoma (NCT02035956). Two patients had a vaccine-related objective response among the five patients with metastatic disease, and the other eight patients who had no detectable disease mostly experienced prolonged disease-free survival. Two-thirds of vaccination developed *de novo* in addition to pre-existing immunity. [@B269] also showed that direct injection of protamine-protected mRNA vaccine is feasible and safe; it can also increase the T cell response and decrease immunosuppressive cells in metastatic melanoma patients (NCT00204607). However, the translational efficiency of RNA vaccine remains challenging as only a small portion of administered mRNA can be captured and presented by APCs. Therefore, Sahin and his group administered the RNA vaccine directly into lymph nodes through ultrasound-guided percutaneous injection, noted as intranodal injection (i.n.).

DC Vaccine {#S4.SS4}
----------

Dendritic cells have a key role in presenting antigens to the immune system. DCs are often recognized as the most potent APCs, which are capable of acquiring and processing antigens for presentation to T cells and expressing high levels of costimulatory molecules ([@B210]). Therefore, vaccination based on DCs is a promising platform for neoantigen vaccine. [@B39] were the first to report autologous DC vaccines directed at tumor amino acid substitutions (AAS) in three melanoma patients (NCT00683670). They filtered the candidate HLA-A^∗^ 02: 01 epitopes containing mutations residues after whole exome sequencing and HLA binding prediction and evaluated the MHC-epitope binding using mass spectrometry. Then they filtered precursors of DCs from patients' bloodstream, matured them and exposed them to synthetic epitopes. The peptide-loaded DCs were then returned to the patients by intravenous infusion. It increased the breadth and diversity of anti-tumor immunity after receiving the DC neoantigen vaccine ([@B39]). However, DC vaccine is laborious, costly and need highly skilled technicians for manufacturing ([@B44]).

Adoptive T Cell Therapy (ACT) {#S4.SS5}
-----------------------------

T cell therapy targeting driver mutations is quite attractive, since they are not only specific and biologically important, but also shared between different patients ([@B141]). Currently, KRAS mutations are hot-spot driver mutations and the most frequent KRAS mutant is KRAS G12D that is expressed in ∼45% of pancreatic adenocarcinomas ([@B31]) and ∼13% of colorectal cancers ([@B260]). [@B207] administered cytotoxic T cells targeting mutant KRAS G12D into a patient with metastatic colorectal cancer (NCT01174121). After whole-exome and transcriptome sequencing of three resected lung lesions, they found that CD8+ T cells in TILs specifically recognized mutant KRAS G12D. Then they selected and expanded TILs that were reactive to the mutant KRAS G12D. The patient received a single infusion of 1.48 × 10^11^ TILs, which contained 1.11 × 10^11^ HLA-C^∗^08:02--restricted CD8+ T cells that specifically targeted KRAS G12D. The objective regression of all seven lung metastases was observed at the first follow-up visit. However, one of these metastatic lesions had progressed when evaluating after 9 months of therapy. The loss of the chromosome 6 haplotype encoding the HLA-C^∗^08:02 class I MHC molecule resulted in progression after resecting this lesion and sequencing, which provides direct evidence of tumor immune evasion ([@B248]). Furthermore, the group used this approach to demonstrate that CD4+ T helper 1 (TH1) cells in TILs recognized a mutation in erbb2 interacting protein (ERBB2IP) in a patient with metastatic cholangiocarcinoma. This patient was treated with mutation-reactive TH1 cells twice and experienced tumor regression (NCT01174121) ([@B249]).

Neoantigen Load Associates With Immune Checkpoint Inhibitors {#S5}
============================================================

Antibodies targeting two immune checkpoints, PD-1 and CTLA-4, represent the greatest success of cancer immunotherapy, which can elicit durable antitumor responses in a wide range of malignancies ([@B87]; [@B81]; [@B43]; [@B184]; [@B200]; [@B286]). The treatment of immune checkpoint inhibitors has improved OS and PFS in many different cancers ([@B202]; [@B244]; [@B26]; [@B28]; [@B67]; [@B115]; [@B201]; [@B232]; [@B70]; [@B242]). Accumulating evidence suggests that cancers with higher mutation burden are associated with more survival benefits from both anti- PD-1 and anti- CTLA-4 therapy ([Table 4](#T4){ref-type="table"}) ([@B81]; [@B11]; [@B198]; [@B6]; Erratum for the Report "Genomic correlates of response to CTLA-4 blockade in metastatic melanoma" by [@B254]; [@B89]; [@B139]; [@B142]; [@B151]; [@B207]). Mutations may increase the possibility of generating immunogenic neoantigens, which facilitate the recognition of cancer cells as foreign ([@B216]; [@B195]). Studies in melanoma patients have demonstrated that neoantigen-specific CD8+ and CD4+ T cells in TILs responded to checkpoint blockade therapy ([@B113]; [@B130]; [@B249]; [@B128]), which provides testimony for the hypothesis. Furthermore, neoantigen loss may contribute to acquired resistance through tumor cell elimination or chromosomal deletions during immune checkpoint blockade therapy ([@B5]); other mechanisms include upregulation of alternate immune checkpoints ([@B109]), loss of HLA haplotypes ([@B133]), or somatic mutations in HLA or JAK1/JAK2 genes ([@B224]; [@B66]). However, a proof-of-concept by Nicholas in which cytotoxic chemotherapy--induced subclonal neoantigens were enriched in certain poor responders to immune checkpoint inhibitors was presented ([@B142]). Additionally, gliomas that recurred after treatment with the DNA alkylating agent temozolomide were identified to carry numbers of mutations ([@B92]; [@B35]), which had a higher mutation burden generated from chemotherapy, but had less clinical benefit. As a result, the association between response to immune checkpoint blockade and neoantigen burden is not linear and clear ([@B117]). [@B138] demonstrated that the number of neoantigens per missense mutation (neoAg frequency) was an independent predictive factor for PFS in ovarian clear cell carcinoma (OCCC), and the low neoAg frequencies were correlated with increased PFS. High mutation and neoantigen load negatively influenced PFS in multiple myeloma (MM) patients, which had a lower mutational burden ([@B147]). [@B131] developed a neoantigen fitness model that could describe the evolutionary dynamics of cancer cells and predict tumor response to checkpoint blockade immunotherapy. Further studies are needed regarding the relationship between neoantigen load and checkpoint blockade immunotherapy.

###### 

Trials defining a TMB threshold for ICB benefit.

  **Cancer type**   **Agents**                 **Methods**     **Threshold defined**   **RR**               **PFS**                  **References**
  ----------------- -------------------------- --------------- ----------------------- -------------------- ------------------------ ----------------
  NSCLC             Pembrolizumab              WES             200 mut                 59% versus 12%       NR versus 3.4 months     [@B198]
  NSCLC             Anti-PD-1 and anti-PD-L1   MSKCC and NGS   7.4 mut/Mb              38.6% versus 25%     --                       [@B197]
  NSCLC             Nivolumab and ipilimumab   WES             158 mut                 51% versus 13%       17.1 versus 3.7 months   [@B84]
  SCLC              Nivolumab and ipilimumab   WES             248 mut                 46.2% versus 21.3%   7.8 versus 1.4 months    [@B85]
  NSCLC             Nivolumab                  WES             \>243 mut               47%versus 23%        HR 0.62                  [@B38]
  NSCLC             Nivolumab and ipilimumab   FM and NGS      \>10 mut/Mb             45.3% versus 24.6%   7.1 versus 3.2 months    [@B86]
  Melanoma          Anti-CTLA-4                WES             100 mut                 --                   --                       [@B227]
  Melanoma          Nivolumab                  WES             100 mut                 --                   --                       [@B196]
  Various cancers   Various immunotherapies    FM and NGS      20 mut/Mb               58% versus 20%       12.8 versus 3.3 months   [@B74]
  UC                Atezolizumab               FM and NGS      16 mut/Mb               --                   --                       [@B14]
  UC                Atezolizumab               FM and NGS      \>9.65 mut/Mb           --                   --                       [@B185]
  UC                Nivolumab                  WES             ≥170 versus \< 85 mut   31.9% versus 10.9%   3 versus 2 months        [@B64]

RR (relative risk), PFS (progression-free survival), NSCLC (non-small-cell lung cancer), SCLC (small-cell lung cancer), UC (urothelial cancer), PD-1 (programmed cell death protein 1), PD-L1 (programmed cell death-ligand 1), CTLA-4 (cytotoxic T-lymphocyte-associated protein 4), WES (whole exome sequencing), NGS (next generation sequencing), FM (foundation medicine), mut (mutation), HR (hazard ratio).

High mutation burden is associated with survival benefits from ICB therapy, but autoantibodies may also predict the efficacy of immune checkpoint inhibitors (ICIs) ([@B54]). However, recent studies have demonstrated that autoantibodies correlate with immune checkpoint therapy-induced toxicities ([@B50]; [@B54]; [@B234]). Since the mechanism of ICB therapy is to mediate non-specific suppression of T cells by negative costimulatory signals, it may break the balance of autoimmunity and lead to the activation of autoreactive B cells that produce autoantibodies ([@B173]; [@B165]). As we know, ICB therapy can cause immune-related adverse events (irAEs), referring to the release of distinctive toxicities including pneumonitis, dermatitis, hepatitis, colitis, and hypophysitis ([@B87]; [@B267]; [@B65]). A recent study found that CD21lo B cells and plasmablasts increased in patients following ICB treatment, and these changes in B cells preceded and correlated with the frequency and timing of irAEs ([@B53]). Besides, one phase I clinical trial including advanced metastatic melanoma patients who received BCG and ipilimumab treatment was suspended due to the occurrence of irAEs. Researchers found profound increases in the repertoire of autoantibodies directed against both selves- and cancer antigens at time points preceded the development of symptomatic toxicity (NCT01838200) ([@B50]). Furthermore, [@B234] also found that anti-GNAL and anti-ITM2B autoantibodies correlated with the development of ICI--related hypophysitis and that anti-CD74 autoantibodies were associated with ICB--induced pneumonitis development. They also tested additional patient samples by enzyme-linked immunosorbent assay to verify these findings ([@B234]). These data suggest that autoantibodies under ICB treatment may serve as a predictive biomarker for irAEs.

Challenges {#S6}
==========

The Challenges With MHC--Peptide-Binding Prediction {#S6.SS1}
---------------------------------------------------

Current neoantigen identification techniques are still time consuming and labourious ([@B247]; [@B76]). The predictors of immunogenicity are immature ([@B36]). In addition, since cytotoxic CD8+ T cells are the main killer of cancer cells, the available computational tools can only predict neo-epitopes that bind to MHC class I molecules presented on CD8+ T cells ([@B156]). Humans have approximately 5,000 alleles encoding MHC class I molecules, with expression of up to six MHC class I molecules ([@B162]) and computational tools cannot predict them all. Intriguingly, even though the epitopes are selected for high MHC class I binding affinity, the neoantigen vaccine trials showed a higher proportion of MHC class II--restricted, CD4+ T cells ([@B110]; [@B168]). Furthermore, studies demonstrated that CD4+ T cells also recognize a higher number of neo-epitopes than was previously known and can confer potent antitumor activity ([@B249]; [@B110]). However, it will be more difficult to develop predictive algorithms for MHC class II molecules ([@B157]). First, MHC class II molecules are heterodimers of alpha and beta peptides encoded by four different loci, with three of them being highly polymorphic in the human genome ([@B204]). Second, the MHC class II binding groove is open on both ends, presenting longer sequences of amino acids (11--20 amino acids or even longer) than MHC class I molecules (8--11 amino acids) ([@B12]; [@B23]). Recently, [@B7] described the method for the quantitative prediction of peptide binding affinity of MHC class II molecules of known sequence.

Primarily, the protein that contains the mutated residue is processed by the proteasome ([Figure 3](#F3){ref-type="fig"}) ([@B159]) ---a catalytic complex in the cytosol that can cleave the amino acid (AA) sequence to peptides ranging from 3 to 22 AA in length ([@B108]; [@B206]; [@B154]). A fraction of the peptides is further trimmed by aminopeptidases and endopeptidases in the cytosol and the endoplasmic reticulum(ER) ([@B19]; [@B278]; [@B276]; [@B205]). Then, this peptide will be transported into the ER lumen by the TAP1/TAP2 transporter to assemble with MHC class I molecules ([@B179]; [@B116]). Finally, the peptide-MHC class I complex can be presented on the cell surface. However, these computational tools hardly consider the endogenous processing and transport of peptides before HLA binding, which results in a high false-positive rate. As studied by Robbins and colleagues, 229 tumor-specific neo-epitopes were predicted in three melanoma patients, but only 11 (4.8%) of these neo-epitopes elicited a T cell response ([@B199]). Neo-epitopes can also be produced by an altered MHC class I processing machinery in cancer cells ([@B258]; [@B218]; [@B255]), which results in a high false-negative rate. Recently, [@B1] developed a new method of liquid chromatography-tandem mass spectrometry (LC--MS/MS) analysis of HLA-associated peptides which takes into account the endogenous processing of peptides, they also developed a new predictor with better algorithm since it is trained on peptide affinity data.

![Schematic diagram illustrates the steps involved in tumor neoantigen processing and presentation on MHC class I molecules.](fcell-08-00728-g003){#F3}

However, some patients may have no expression or aberrated expression of MHC molecules as immune evasion mechanisms ([@B135]; [@B69]; [@B121]; [@B238]). The loss of MHC class I can be detected in the early stage of some cancers ([@B262]; [@B257]). As studied by [@B34], β2m mutations and LMP7/TAP2 downregulation are the two main mechanisms in colorectal cancer that are responsible for the loss of MHC surface expression, and thus T cells fail to recognize cancer cells during an immune response. In some tumors, the MAPK pathway may regulate MHC I presentation ([@B148]; [@B27]; [@B60]). After the mutated peptide and MHC class I complex presenting on the tumor cell surface, T cell recognition can occur only when TCRs that have the ability to recognize the mutant epitope exist within the T cell repertoire. Luckily, prior data showed that the T cell repertoire had a diversity of ∼2.5 × 10^7^ ([@B10]), and a single TCR was able to recognize up to 10^6^ different MHC/peptide complexes, and thus the immune system could recognize ∼10^12^ possible foreign epitopes ([@B137]), which means the immune system has a strong recognition ability to distinguish even minor variations in MHC/peptide complexes. A study has shown that only certain types of mutations can be missed, such as conservative substitutions at other positions or alterations at the N-terminal peptide residue ([@B105]).

Tumor Heterogeneity {#S6.SS2}
-------------------

Genomic instability and mutational processes can result in extensive tumor heterogeneity in each patient ([@B71]). First, spontaneous mutations occur during the stages of tumor progression. Second, tumor microenvironments such as T cells can mediate neoantigen immunoediting ([@B261]) or neoantigen loss. Third, metastatic lesions can involve the distal outgrowth of tumor cells originated from a subclone of the primary tumor; although there is little heterogeneity in driver mutations, there is still considerable epigenetic reprogramming between primary and metastatic tumors as studied in pancreatic ductal adenocarcinoma (PDAC) ([@B3]). Therefore, a single site tumor biopsy may not adequately capture the total number of antigen clones present in the tumors ([@B214]). It is well established that intratumor heterogeneity (ITH) correlates with the response of cancer patients to treatments with targeted therapies ([@B56]; [@B223]; [@B114]). This is only tumor heterogeneity for each individual patient. For different patients and different cancers, the neo-epitopes were rarely shared except for driver mutations, which account for a fraction of mutations. [@B42] analyzed more than 8,000 patients comprising 20 solid cancers from the TCGA (results available at <https://tcia.at/>). The pan-cancer analysis showed that the fraction of neo-epitopes generated from driver genes was 7.6%. Only 24 of 911,548 unique predicted neo-epitopes were common in more than 5% of patients ([@B42]). Therefore, neoantigen immunotherapy will probably need to be fully personalized for each patient, and this will be the next generation of precision medicine.

Tumor Suppression Environment {#S6.SS3}
-----------------------------

Cancer immunotherapy can offer limited clinical benefit without mitigating the immunosuppressive microenvironment of tumors. It has been increasingly recognized that tumors develop a specialized niche termed the tumor microenvironment (TME) in which tumor cells are protected from therapeutic interventions ([@B190]). This niche includes fibroblasts ([@B102]; [@B45]), myeloid suppressor cells (MDSCs) ([@B73]; [@B112]), regulatory T (Treg) cells ([@B256]; [@B25]), tumor-associated macrophages (TAM) ([@B189]; [@B171]), lymphocytes, the extracellular matrix (ECM) and abnormal blood and lymphatic vessels ([@B95]). For example, high stromal density can limit T cell access to tumor cells and delivery of cytotoxic agents that provide a barrier ([@B188]; [@B61]; [@B169]). Cancer cells can also express ligands for inhibitory receptors on T cells and secrete a multitude of chemokines and cytokines to affect antitumor immunity ([@B265]; [@B239]). The vaccine strategies can successfully increase the frequency and activity of T cells, but they fail to guarantee that these T cells can exert their function within the tumors. The most important reason is the immune escape mechanisms in cancers, and thus proper co-treatment during vaccination is needed ([@B9]; [@B255]). Other than ICIs, there are multiple inhibitors targeting tumor immunosuppressive factors, including IDO1 inhibitors ([@B228]), MEK inhibitors ([@B60]), colony-stimulating factor-1 receptor (CSF1R) and chemokine (C-C motif) receptor 2 (CCR2) inhibitors ([@B149]), tumor extracellular matrix and stromal inhibitors ([@B188]), adenosine signaling through the adenosine A2a receptor (A2aR) ([@B122]), and other metabolic signaling pathways ([@B172]). In addition, combining such TME modulators with neoantigen-specific therapy may augment antitumor immunity ([@B144]). As studied by [@B285] CSF1R blockade could significantly improve the efficacy of PD-1 or CTLA-4 antagonists on tumor regressions. Furthermore, among the large number of predicted epitopes, only a minority can be recognized by autologous T cells ([@B199]; [@B259]; [@B198]); therefore, one group has proved that T cells redirected with T cell repertoires of healthy blood donors can efficiently recognize cancer epitopes that are neglected by a patient's autologous T cells ([@B231]).

Conclusion and Perspectives {#S7}
===========================

Personal neoantigen vaccines can elicite strong T cell responses, which not only expand existing neoantigen-specific T cell populations, but also induce a new proportion of specific T cells in cancer patients ([@B168]). Hence, the identification of neoantigens is of utmost importance to improve cancer immunotherapy and broaden its efficacy to a larger number of patients. [@B106] discovered that immunoglobulin neoantigens in human mantle-cell lymphomas and CD4+ T cells specific for the neoantigens could mediate killing of autologous lymphoma cells. [@B104] also demonstrated that a strategy using multi-epitope, personalized neoantigen vaccination is feasible not only for high-risk melanoma ([@B198]; [@B168]; [@B212]) but also for glioblastoma ([@B104]), which has a relatively low mutation load. Furthermore, [@B13] identified MUC16 as immunogenic hotspots in long-term survivors of pancreatic ductal adenocarcinoma, which is a presumed poorly immunogenic and checkpoint blockade-refractory tumor. These results are encouraging, but efforts are needed to tackle those challenges, and we will be very likely to witness these exciting developments in the near future.
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